(Q36793661)

16 August 2017

1 reference

title

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies (English)

1 reference

16 August 2017

1 reference

1 reference

1 reference

3

Heinz-Josef Lenz

1 reference

16 August 2017

Wu Zhang

1

1 reference

PubMed ID

17438669

16 August 2017

Michael Gordon

series ordinal

2

1 reference

PubMed ID

17438669

16 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

16 August 2017

1 reference

16 August 2017

38

1 reference

16 August 2017

545-551

1 reference

16 August 2017

8

1 reference

16 August 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Chemoprevention of breast cancer: a model for change

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630601070812

10.1080/09546630601070812

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17438669